Yosemite provides unrestricted grants to academic scientists, de-risking novel research and building relationships. This early support creates a unique deal flow engine, leading to investment opportunities in companies that later spin out from this foundational work.

Precursor Ventures makes "directional people bets" by investing smaller checks ($150-250K) in top-tier founders to fund their search for a viable business concept. This strategy prioritizes founder quality over the initial idea, recognizing that great founders can pivot to find product-market fit.

Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.

Rather than competing in crowded auctions, elite private equity firms pursue a differentiated "executive new build" strategy. They partner with proven operators to build new companies from scratch to address a market need, creating proprietary deals that other firms cannot access.

Top VCs are reviving the early, hands-on model of pioneers like Arthur Rock. Instead of just investing, firms are co-designing new labs from scratch, providing compute, capital, and commercial guidance. This "company creation" approach is viable again as capital is no longer the primary bottleneck for ambitious, frontier-tech ideas.

When evaluating founders coming from academia, VCs should distinguish between those fixated on a niche problem and those driven by real-world impact. The latter are more likely to find a problem that generates revenue and successfully transition from a science project to a viable company.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

A primary strategy for early-stage investment is partnering with entrepreneurs with a successful track record, often from previous portfolio companies. VCs will back a person they trust, like a former Chief Scientific Officer or a repeat founder, valuing proven execution experience sometimes even more than a nascent scientific concept.

The most potent source of new, truly cutting-edge investment opportunities isn't inbound emails or demo days, but rather the networks of the exceptional founders and scientists you've already backed. These individuals are at the frontier and can identify the next wave of talent.